ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Institution	Shares	Value	Change
BlackRock	2,958,646	$245M	INCREASED
Vanguard	1,404,628	$116M	INCREASED
Soleus Capital Management	867,760	$72M	INCREASED
State Street	831,647	$69M	INCREASED
Tang Capital Management	707,500	$59M	UNCHANGED

ANI Pharmaceuticals, Inc. (ANIP) Ownership & Trading Activity

Top Institutional Holders